Battelle excels in pulmonary drug delivery.

Battelle establishes innovative partnerships, providing best-in-class technical performance in nonclinical safety assessment, biotechnology, clinical trials management, and health outcomes research and evaluation. We integrate drug development processes to reduce time involved for nonclinical drug development. For example, a 1996 toxicology/pharmacokinetics project with a protein drug administered by continuous infusion proceeded to clinical trials in only seven months. Another program, completed within nine months, included two administration routes, mass spectroscopy method development, and safety pharmacology. In a collaborative biotechnology program, Battelle applies AxCell Biosciences Corporation's functional genomics technology to isolate genes with potential therapeutic relevance. This work identifies targets for cancer, neuro-degenerative diseases, hypertension, and other diseases. Also in 1996, Battelle co-developed a technology for non-invasive pulmonary drug delivery. We added value by creating proprietary efficacy models and expanding the types of drugs to be delivered. Battelle has an extensive network to access pulmonary delivery technologies for specific drug delivery applications. In addition, Battelle conducts quality-of-life, health outcomes, and cost-effectiveness research. For two large, U.S.-based pharmaceutical companies, Battelle is collecting data from 35 managed care organizations (MCOs) to analyze the efficacy and cost-effectiveness of trial drugs. These data are used to calculate direct and indirect costs for health care utilization. Battelle also collects indirect trial outcomes using computer-assisted telephone interviewing.

Battelle discovers molecular targets for new drugs by applying AxCell's functional genomics technology. Battelle extracts and standardizes electronic MCO patient data for clinical trials and outcomes research.